BlossomHill Therapeutics (BLSM) reported a Q2 loss on Friday of $8.75 per share, widening from a loss of $5.51 a year earlier.
One analyst polled by FactSet expected a GAAP loss of $0.77.
The company did not report any revenue for the quarter.
Cash and cash equivalents for the quarter ended June 30 totaled $95.4 million, which, together with proceeds from its recent IPO, should be sufficient to fund operations into Q2 2028, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.